We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
With the threat of COVID-19 still looming in many communities across the U.S. and uncertainty over its future path, now more than ever, it's critical for people to get a flu shot.
Several drugmakers are already stockpiling drugs in case of a no-deal Brexit. However, one crucial product simply cannot be reserved because it’s not possible to be made in advance: the seasonal flu vaccine.
As flu-vaccine heavyweights dispatch their first doses for the upcoming season, they're planning millions more doses made with next-generation production processes, rather than traditional egg-based manufacturing.